JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Exploring SSR1 as a novel diagnostic and prognostic biomarker in hepatocellular carcinoma, and its relationship with immune infiltration

  • 0Department of Blood Transfusion, Shenzhen Baoan Shiyan People's Hospital, Shenzhen, China.
Translational Cancer Research +

|

November 11, 2024

|

November 11, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Signal sequence receptor subunit 1 (SSR1) is a novel biomarker for hepatocellular carcinoma (HCC). Elevated SSR1 indicates poor prognosis and is linked to tumor progression and immune cell infiltration in HCC.

Area Of Science

  • Oncology
  • Molecular Biology
  • Cancer Research

Background

  • Signal sequence receptor subunit 1 (SSR1) role in hepatocellular carcinoma (HCC) is understudied.
  • Investigating SSR1 in HCC is crucial for understanding cancer progression.

Purpose Of The Study

  • To explore SSR1's role in HCC progression.
  • To elucidate the molecular mechanisms of SSR1 in HCC.

Main Methods

  • Utilized ONCOMINE, TIMER, and TCGA databases for SSR1 expression analysis.
  • Performed survival analyses, nomograms, ROC curves, GO, and GSEA for prognostic and diagnostic evaluation.
  • Conducted in vitro experiments to assess SSR1's impact on HCC proliferation and migration.

Main Results

  • Elevated SSR1 correlates with advanced clinical parameters and reduced overall survival in HCC patients.
  • SSR1 identified as an independent prognostic marker with high diagnostic accuracy.
  • SSR1 associated with epithelial-mesenchymal transition (EMT) pathway and altered immune cell infiltration.

Conclusions

  • SSR1 is a promising diagnostic and prognostic biomarker for HCC.
  • SSR1 is linked to immune cell infiltration and proliferation in HCC.
  • SSR1 may influence HCC progression via the EMT pathway.

Keywords: